Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
Biogen said on Tuesday that it would replace its chief executive and effectively give up on marketing a high-profile Alzheimer’s drug that has been a commercial failure since its controversial approval nearly a year ago. Michel Vounatsos, who has led the drug maker for over five years and presided over the approval and launch of…